In August 2023, the Department of Health and Human Services recommended that the DEA move cannabis from Schedule I to Schedule III. The recommendation followed a review process that had been ongoing since October 2022. As of early 2026, the rescheduling process remains incomplete — stalled in public comment periods, legal challenges, and bureaucratic procedure.

This matters for the broader entheogenic governance conversation because it reveals a structural problem: the scheduling framework itself may be inadequate for substances whose primary value is not recreational or even strictly medical, but rather therapeutic, sacramental, or consciousness-related.

The Schedule I Bottleneck

Under the Controlled Substances Act, Schedule I classification means a substance has “no currently accepted medical use” and “a high potential for abuse.” This classification creates a catch-22: researchers need Schedule I substances to prove medical value, but Schedule I classification makes research prohibitively difficult.

For psilocybin, MDMA, and other entheogenic compounds, the scheduling bottleneck has delayed decades of potential research. When Johns Hopkins and NYU finally received permission to study psilocybin for depression and end-of-life anxiety, the results were remarkable — but the approval process took years of navigating DEA licensing, FDA protocols, and institutional review boards designed for pharmaceutical development, not consciousness research.

What Rescheduling Actually Changes (And What It Doesn’t)

Moving a substance from Schedule I to Schedule III:

Changes:

  • Reduces regulatory burden on researchers (easier DEA licensing)
  • Allows physicians to prescribe (under certain conditions)
  • Opens limited commercial production

Does not change:

  • The fundamental framework of scheduling as a governance tool
  • The assumption that all psychoactive substances fit neatly into pharmaceutical categories
  • The exclusion of sacramental, ceremonial, or integration-focused use from the legal framework
  • The need for standardized, patentable formulations (which may not serve plant medicines well)

The Deeper Question

The scheduling debate often obscures a more fundamental governance question: are controlled substance schedules the right tool for governing compounds whose primary use cases include religious ceremony, psychological healing, creativity, and consciousness exploration?

Alcohol and tobacco — substances with well-documented harm profiles — exist entirely outside the scheduling framework. Caffeine, arguably the most widely used psychoactive substance on earth, is unscheduled. The scheduling system was designed in 1970 to address street drugs and pharmaceutical diversion, not to govern a category of substances that indigenous cultures have used sacramentally for millennia.

What Scholars and Journalists Should Watch

  1. State-level decriminalization continues to outpace federal action. Oregon (Measure 109), Colorado (Proposition 122), and several cities have created legal frameworks that don’t depend on federal rescheduling.

  2. FDA breakthrough therapy designations for MDMA-assisted therapy and psilocybin-assisted therapy signal that the pharmaceutical pathway is advancing — but pharmaceutical framing may limit access to those who can afford clinical settings.

  3. Religious freedom claims under RFRA and the First Amendment are being tested in courts by groups seeking legal protection for entheogenic ceremonies outside the pharmaceutical framework.

  4. International precedents — Jamaica, the Netherlands, and several Latin American countries offer regulatory models that don’t rely on the US scheduling framework.

The scheduling question isn’t just about which schedule a substance belongs on. It’s about whether scheduling is the right question at all.

Sources and further reading available upon request. Entheo.News is a documentation archive for journalists, scholars, and legal researchers.